Is NO an endogenous antiatherogenic molecule?
- 1 May 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
- Vol. 14 (5), 653-655
- https://doi.org/10.1161/01.atv.14.5.653
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in NeurotoxicityScience, 1994
- NITRIC OXIDE—A NEW ENDOGENOUS IMMUNOMODULATORTransplantation, 1993
- L-Arginine Inhibits Balloon Catheter-Induced Intimal HyperplasiaBiochemical and Biophysical Research Communications, 1993
- L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.Journal of Clinical Investigation, 1992
- Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit.Journal of Clinical Investigation, 1992
- Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase.Journal of Clinical Investigation, 1992
- Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginineThe Lancet, 1991
- Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.Journal of Clinical Investigation, 1989
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987
- Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulfur prosthetic group and is reversible.Journal of Clinical Investigation, 1986